Table 1.
In vivo | Acetone | AcAc | BHB | References |
---|---|---|---|---|
Induced Seizures | ||||
Thujone | + | + | − | a, b |
Audiogenic | + | + (BD-AcAc2, AS mice) | − | c, m |
MES | + | N.D. | N.D. | d |
PTZ | + | + (BD-AcAc2) | N.D. | d, e, g, k, l |
Amygdala Kindling | + | N.D. | N.D. | d |
AY-9944 | + | N.D. | N.D. | d |
4-AP | + | + | N.D. | e, h |
Li-pilo SE | + | N.D. | N.D. | f |
Hyperbaric Oxygen | N.D. | + (BD-AcAc2) | − (1,3-butandiol) | j |
Kainate | N.D. | + (BD-AcAc2, AS mice) | N.D. | m |
Repeated flurothyl | N.D. | N.D. | + (rat neonates) | n |
Spontaneous Seizures | ||||
Intrahippocamapal Kainate | N.D. | + | N.D. | i |
betamethasone-NMDA | N.D. | N.D. | + | o |
Kcna1-null mice | N.D. | N.D. | + | p |
| ||||
In vitro | Acetone | AcAc | BHB | References |
| ||||
Cellular and population excitability | ||||
mEPSCs | N.D. | + | N.D. | h |
Field Potentials | N.D. | − | − | q, p, s |
Population Spikes | N.D. | − | − | q, s |
LTP | N.D. | − | − | p, r, s |
Mitochondrial mediated synaptic dysfunction | ||||
ETC inhibitors | N.D. | + | + | p, r, v |
ROS | N.D. | + | + | p, u, v |
Induced Seizure-like events in slices | ||||
4-AP | N.D. | N.D. | − | w |
Low Mg2+ | N.D. | N.D. | − | t, w |
PTZ | N.D. | − | − | t |
bicuculline | N.D. | N.D. | − | |
High frequency stimulation | N.D. | N.D. | − | w |
OGD | N.D. | N.D. | + | w |
Kcna1-null mice | N.D. | + | + | p |
Abbreviations: AcAc, acetoacetate; BHB, β-hydroxybutyrate; MES, maximal electroshock; PTZ, pentylenetetrazole; 4-AP, 4-aminopyridine; Li-pilo, lithium pilocarpine; SE, status epilepticus; HFS, high-frequency stimulation; OGD, Oxygen-glucose deprivation; N.D., not determined; +, attenuation effect; −, inactive; BD-AcAc2, R,S-1,3-butanediol acetoacetate diester; AS, Angelman syndrome; mESPC, miniature excitatory post-synaptic current; LTP, long-term potentiation; ETC, electron transport chain; ROS, reactive oxygen species.
a. Keith, 1933
b. Keith, 1935
m. Ciarlone et al., 2017